NEW YORK, Sept. 16, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that it has appointed Mark Davison as the Head of its CNS division.
Mark Davison has over sixteen years' experience in the pharmaceutical industry. He started his scientific career at SmithKline Beecham (now part of GSK) in drug discovery research and project management. He also worked on the biosynthetic pathway for the blockbuster drug Augmentin. The team helped to increase process yields of this important drug and so reduce cost-of-goods. He then joined Inveresk (now part of Charles River) and held various business development and strategic planning roles. His role involved developing new business for what was initially a fairly small clinical operation. He then joined Quintiles Transnational as director of business development, latterly responsible for their largest ($40m per annum) European account. He previously had responsibility for business development for their largest therapeutic franchise. He is very experienced in drug development and the needs of small biotechnology companies, and his CRO experience gives valuable insight into the efficient use of outsourcing to achieve development goals.
Mark Davison as Head of CNS joins Dr. Nigel Rulewski as Head of Oncology, Dr. Bruce Murdoch as Head of Anti-Infective, Bernard Ross as Head of Cardiovascular, and Dr. Chris O'Toole as head of Specialty Pharma.
About Bioaccelerate
Bioaccelerate Holdings Inc. (OTCBB:BACL) is a pharmaceutical development organization ("PDO") that seeks to acquire, develop and commercialize novel pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate uses its broad network of academic, industry and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries. The company holds majority equity interests in 10 biopharmaceutical companies, three of which are public, and holds minority interests in four biopharmaceutical companies, two of which are public. The company also holds a minority equity interest in a public nanotechnology company. Bioaccelerate's strategy relies on its development network for research, clinical development and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin Board under the symbol "BACL." For more information on Bioaccelerate, visit the company's website at http://www.bioaccelerate.com.
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and in Bioaccelerate's compounds under development in particular; the potential failure of Bioaccelerate's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioaccelerate's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioaccelerate's business, structure or projections; the development of competing products; uncertainties related to Bioaccelerate's dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under Bioaccelerate's prior name Mobile Design Concepts, Inc. Bioaccelerate disclaims any obligation to update these forward-looking statements.